Table Graph
      published meta-analysis   sensitivity analysis   studies

Sinopharm Wuhan in COVID-19 prophylaxis (excluding children) - Summary of results

OutcomeTE95% CInkI2ROBPub. bias hospitalizationdetailed resultsSinopharm Wuhan Vero cell, 2021 0.21 [0.06; 0.75] 0.21[0.06; 0.75]Sinopharm Wuhan Vero cell, 202110%27,530NAnot evaluable symptomatic Covid-19detailed resultsSinopharm Wuhan Vero cell, 2021 0.22 [0.14; 0.35] 0.22[0.14; 0.35]Sinopharm Wuhan Vero cell, 202110%27,530NAnot evaluable severe COVID-19 occurrencedetailed resultsSinopharm Wuhan Vero cell, 2021 0.25 [0.01; 5.54] 0.25[0.01; 5.54]Sinopharm Wuhan Vero cell, 202110%27,530NAnot evaluable0.02.01.0relative treatment effectwww.metaEvidence.org2024-05-09 19:48 +02:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 89 - treatments: 761 - roots T: 290

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons